Mitochondrial Antioxidant therapy to Resolve Inflammation in Ulcerative Colitis (Mini-MARVEL): A Phase 2b feasibility randomised placebo controlled trial of oral MitoQ in mild-to-moderately active paediatric UC. Mini-MARVEL aims to assess the acceptability and practicality of delivering the intervention (MitoQ or placebo as add-on therapy) in a multi-centre UK placebo-controlled RCT in paediatric UC, and to estimate parameters for a possible larger study of this add-on therapy to conventional medical therapy in a multi-centre RCT. We will also obtain information on possible effectiveness of the repurposed drug MitoQ as an add-on to standard therapy compared to placebo add-on in mild-moderately active paediatric UC, to investigate effectiveness, safety and tolerability of MitoQ in UC, and also the effect on steroid burden and quality of life (QoL). Chief Investigator: Gwo-Tzer Ho Image Number and location of participating sites (by region/ country): 10 UK sites EudraCT number: 2021-005010-34 Funder: JP Moulton Foundation Trust Start and End date Of grant award: August 2019 Of recruitment: TBC Current Status: In set up Sponsor Representative: ACCORD https://www.accord.scot/ Chief Investigator Gwo-Tzer Ho, Centre for Inflammation Research, QMRI, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh, EH16 4TJ, G.Ho@ed.ac.uk Trial Manager Lisa Derr, Edinburgh Clinical Trials Unit, Usher Building, The University of Edinburgh, 5-7 Little France Road, Edinburgh BioQuarter - Gate 3, Edinburgh EH16 4UX lisa.derr@ed.ac.uk UK GDPR Privacy Statement: Within patient information leaflet ECTU involvement: Trial management / Statistics / Database (UKCRC) This article was published on 2024-09-24
